



FINANCIAL TEAR SHEET

Corporate Profile

Apricus is committed to developing sexual health therapies in areas of high unmet needs. We have disciplined leadership focused on execution and are driving near-term shareholder value through regulatory approval, commercialization and partnering initiatives.

Stock Performance

APRI (Common Stock)

Exchange	NASDAQ (US Dollar)
Price	\$0.24
Change (%)	▼ 0.02 (7.69%)
Volume	698,197
52 Week High	\$3.34
52 Week Low	\$0.18
Market Cap	\$6,706,641
Rolling EPS	-0.53
PE Ratio	0
Shares Outstanding	28,167,329

Data as of 01/18/19 3:57 p.m. ET



Recent Headlines

01/15/19
[Apricus Biosciences Stockholders Approve Proposed Merger with Seelos Therapeutics, Inc.](#)

12/14/18
[Apricus Biosciences Adjourns Special Meeting of Stockholders to New Date](#)

12/10/18
[Apricus Biosciences Reminds Shareholders to Vote Before the Special Meeting on December 14, 2018](#)

Upcoming Events

There are currently no events scheduled.

SEC Filings

Filing Date	Form
01/16/19	8-K
01/16/19	425
01/04/19	425
01/04/19	8-K

Data provided by Nasdaq. Minimum 15 minutes delayed. [View Attributions and Sources](#)

© Apricus Biosciences, Inc.